Obesity and Its Impact on Adverse In-Hospital Outcomes in Hospitalized Patients With COVID-19

Keller, Karsten; Sagoschen, Ingo; Schmitt, Volker H.; Sivanathan, Visvakanth; Espinola‐Klein, Christine; Lavie, Carl J.; Münzel, Thomas; Hobohm, Lukas

doi:10.3389/fendo.2022.876028

Cited by 20 publications

(25 citation statements)

References 76 publications

(148 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another key factor is the change regarding the focus of the health care service [ 14 , 15 ]. In order to encounter the consequences caused by the COVID-19 pandemic, the health care systems have changed the organization and management of the health institutions with focus on the COVID-19 pandemic [ 4 , 14 , 37 ]. This changed organization had an important impact regarding the diagnosis and treatment of patients with other prevalent, acute or chronic diseases that carry an increased risk for adverse outcomes with and without co-prevalence of COVID-19, but especially in patients with COVID-19 infection, in whom these other acute and chronic diseases might be overlooked, considered to be unimportant at this time or be unnoticed [ 4 , 14 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

“…During December 2019, pneumonia cases caused by a previously unknown virus occurred in China [ 1 , 2 , 3 , 4 ]. In Germany, the first patient with SARS-CoV-2 infection was identified at the end of January 2020 in Bavaria [ 3 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

“…In Germany, the first patient with SARS-CoV-2 infection was identified at the end of January 2020 in Bavaria [ 3 , 5 ]. This initial cluster of coronavirus disease 2019 (COVID-19) was the starting point of a sustained transmission of SARS-CoV-2 resulting in spread of COVID-19 across the German population [ 3 , 4 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Temporal Trends in Patients with Peripheral Artery Disease Influenced by COVID-19 Pandemic

Keller

Schmitt

Hobohm

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Background: The COVID-19 pandemic influences the health care management of acute and chronic diseases. Data concerning the influence of the pandemic on hospitalizations of patients with peripheral artery disease (PAD) are sparse. Methods: We analysed all patients hospitalized due to PAD between 1 January 2019 and 31 December 2020 in Germany. Hospitalizations of PAD patients during the pre-pandemic year 2019 were compared to the pandemic year 2020. Results: Overall, 361,029 hospitalizations of PAD patients in the years 2019 and 2020 (55.4% aged ≥70 years; 36.6% females) were included in this study. In the pre-pandemic year of 2019, a total of 25,501 (13.2%) more hospitalizations due to PAD were detected compared to the COVID-19 pandemic year of 2020 (2019: 192,765 [53.4%] vs. 2020: 168,264 [46.6%], p = 0.065). Overall, in 610 (0.4%) of the hospitalization cases, a COVID-19 infection was diagnosed. Regarding interventional/surgical treatments, total numbers of peripheral endovascular intervention of the lower extremity decreased by 9.9% (83,845 vs. 75,519, p < 0.001), surgical peripheral artery revascularization of the lower extremity by 11.4% (32,447 vs. 28,754, p = 0.041) and amputations by 4.0% (20,612 vs. 19,784, p < 0.001) in 2020 compared to 2019. The case fatality rate (2.6% vs. 2.4%, p < 0.001), as well as MACCE rate (3.4% vs. 3.2%, p < 0.001), were slightly higher during the pandemic year 2020 compared to the pre-pandemic year 2019. Conclusions: The COVID-19 pandemic influenced the number of hospitalizations of PAD patients with a 13.2% reduction in hospital admissions and decreased total numbers of revascularization and amputation treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Temporal Trends in Patients with Peripheral Artery Disease Influenced by COVID-19 Pandemic

Keller

Schmitt

Hobohm

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…We are not able to clearly distinguish patients with preserved, mid-range and reduced ejection fraction. Body mass index as important characteristic of heart failure population ( 30 ) and negative prognostic factor of COVID-19 ( 31 ) was not known and not included in the analysis. It was also hypothesized that physical activity and air pollution could play a role in the spread of the virus ( 32 , 33 ), our data do not allow us identifying patients who live in geographic areas with increased air pollution.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: A population-based study

Pařenica

Benešová²,

Radvan³

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundHeart failure (HF) patients are at higher risk of severe coronavirus disease 2019 (COVID-19). The Omicron variant has many novel mutations including those in the spike protein, leading to questions about vaccine effectiveness. The aim of this analysis was to evaluate the effectiveness of the COVID-19 vaccine with or without a booster (i.e., after the third dose) during the Omicron variant wave.MethodsChronic heart failure patients in the Czech Republic were included in the analysis. COVID-19 infection was monitored from January 1st 2022 to March 31st 2022. The analysis was conducted on data collected in the National Health Information System. Vaccine effectiveness of vaccinated (with or without booster) vs. unvaccinated patients was analyzed for incidence of COVID-19, COVID-19-related hospitalizations, COVID-19 related intensive care unit admissions, and COVID-19 related mechanical ventilation/extracorporeal membrane oxygenation treatment.FindingsFrom a total 165,453 HF patients in the Czech Republic, 9,728 contracted COVID-19 (22.9% of them not vaccinated, 23.2% vaccinated and 53.8% vaccinated and boosted). Risk of intensive care unit (ICU) hospitalization was 7.6% in the unvaccinated group, 4.8% in the vaccinated group and 2.9% in the boosted group. The calculated effectiveness of the COVID-19 vaccine in prevention of ICU hospitalization in the vaccinated group was 41.9 and 76.6% in the boosted group.InterpretationThe results demonstrated moderate vaccine effectiveness in the prevention of severe COVID-19 in vaccinated but not boosted HF patients. Much stronger effectiveness was found in those who were vaccinated and boosted.

show abstract

“…The association between HTN and COVID-19 is not necessarily causal. HTN occurs more commonly in the elderly and in patients with other comorbidities, including increased adiposity (since fat cells have higher concentration of ACE-2 receptors than the lungs, worsening COVID-19 prognosis [15,16]), all of which are associated with increased risk of severe COVID-19 [17]. In an observational study of 12 594 patients conducted in New York City, a history of HTN was reported 34.6% [18].…”

Section: Hypertension and Coronavirus Disease 2019mentioning

confidence: 99%

Coronavirus disease 2019, hypertension, and renin–angiotensin–aldosterone system inhibitors

Rizk

Sanchís-Gomar

Henry

et al. 2022

Current Opinion in Cardiology

Self Cite

View full text Add to dashboard Cite

Purpose of reviewThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mostly uses the angiotensin-converting enzyme 2 (ACE-2) as cellular receptor for entering the host cells. Some, but not all, animal studies have shown that renin–angiotensin–aldosterone system (RAAS) inhibitors can increase ACE-2 expression. On that premise, it was hypothesized that these agents could make it more likely to develop coronavirus disease 2019 (COVID-19). On the other hand, there was also evidence that being on these agents could lessen the severity of the lung injury in patients with severe SARS-CoV-2 infection. Herein, we review the available evidence on the role of RAAS inhibitors on SARS-CoV-2 and COVID-19 development.Recent findingsRecent randomized controlled trials demonstrate that RAAS blockade or withdrawal does not influence the severity of COVID-19 in patients who are already on these medications. Currently, there is no evidence to support stopping RAAS inhibitors in patients hospitalized for COVID-19. Several questions still need to be addressed. Ongoing studies are currently evaluating the de novo use of RAAS inhibitors in patients with COVID-19. Another area that needs to be investigated is whether or not using these medications increase the risk of infection.SummaryThe wealth of evidence indicates that ACE inhibitors and angiotensin-receptor blocker administration has no harmful effects on hospitalizations and severity of COVID-19 in patients already on these medications and might even reduce mortality among hypertensive patients diagnosed with COVID-19. More evidence and data need to be collected, and at this time, these agents should not be discontinued.

show abstract

Obesity and Its Impact on Adverse In-Hospital Outcomes in Hospitalized Patients With COVID-19

Cited by 20 publications

References 76 publications

Temporal Trends in Patients with Peripheral Artery Disease Influenced by COVID-19 Pandemic

Temporal Trends in Patients with Peripheral Artery Disease Influenced by COVID-19 Pandemic

COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: A population-based study

Coronavirus disease 2019, hypertension, and renin–angiotensin–aldosterone system inhibitors

Contact Info

Product

Resources

About